Beck Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Beck Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-47,350	Closed	-$2.26M	–	96
2019 Q1	$2.26M	Buy	+47,350	New	+$2.36M	1.08%	43
2016 Q1	–	Sell	-8,680	Closed	-$597K	–	96
2015 Q4	$597K	Buy	+8,680	New	+$574K	0.35%	64

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Beck Capital Management's BMY Position: Q2 2019 in Review

Beck Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2019, closing a stake of 47,350 shares — an estimated $2.26M sold.

Beck Capital Management first reported a position in BMY in Q4 2015 and held it in 2 quarters. The position peaked at $2.26M in Q1 2019. 1,777 funds tracked by Wall St. Rank hold BMY as of Q2 2019.

Beck Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2019 after selling out during the quarter.
Beck Capital Management sold 47,350 Bristol-Myers Squibb shares in Q2 2019, an estimated $2.26M.
Beck Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 2 quarters.
Beck Capital Management's Bristol-Myers Squibb position peaked at $2.26M in Q1 2019.
1,777 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2019.

Based on Beck Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.